Eads & Heald Wealth Management’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.13M Sell
4,331
-12
-0.3% -$6.51K 1.06% 35
2025
Q4
$2.52M Sell
4,343
-11
-0.3% -$6.22K 1.22% 25
2025
Q3
$2.11M Sell
4,354
-17
-0.4% -$7.91K 1.01% 34
2025
Q2
$1.77M Sell
4,371
-92
-2% -$38.5K 0.88% 48
2025
Q1
$2.22M Sell
4,463
-49
-1% -$26.5K 1.13% 29
2024
Q4
$2.35M Buy
4,512
+37
+0.8% +$20.3K 1.15% 28
2024
Q3
$2.77M Sell
4,475
-234
-5% -$139K 1.31% 16
2024
Q2
$2.6M Sell
4,709
-47
-1% -$26.9K 1.26% 20
2024
Q1
$2.76M Sell
4,756
-284
-6% -$159K 1.29% 19
2023
Q4
$2.67M Sell
5,040
-30
-0.6% -$14.5K 1.29% 22
2023
Q3
$2.57M Sell
5,070
-123
-2% -$65.5K 1.35% 17
2023
Q2
$2.71M Sell
5,193
-277
-5% -$149K 1.33% 18
2023
Q1
$3.15M Sell
5,470
-59
-1% -$33.3K 1.56% 3
2022
Q4
$3.04M Buy
5,529
+18
+0.3% +$9.54K 1.55% 3
2022
Q3
$2.79M Sell
5,511
-190
-3% -$106K 1.59% 5
2022
Q2
$3.1M Sell
5,701
-78
-1% -$42.9K 1.67% 2
2022
Q1
$3.41M Sell
5,779
-220
-4% -$126K 1.58% 3
2021
Q4
$4M Sell
5,999
-187
-3% -$117K 1.74% 3
2021
Q3
$3.53M Sell
6,186
-239
-4% -$131K 1.71% 1
2021
Q2
$3.24M Sell
6,425
-51
-0.8% -$24.1K 1.58% 3
2021
Q1
$2.96M Sell
6,476
-145
-2% -$69.2K 1.52% 3
2020
Q4
$3.08M Sell
6,621
-418
-6% -$196K 1.66% 3
2020
Q3
$3.11M Sell
7,039
-1,143
-14% -$472K 1.86% 3
2020
Q2
$2.96M Sell
8,182
-319
-4% -$107K 1.8% 3
2020
Q1
$2.41M Sell
8,501
-745
-8% -$235K 1.7% 5
2019
Q4
$3M Sell
9,246
-117
-1% -$35.5K 1.59% 3
2019
Q3
$2.73M Sell
9,363
-305
-3% -$87.3K 1.52% 5
2019
Q2
$2.84M Sell
9,668
-568
-6% -$156K 1.61% 2
2019
Q1
$2.8M Sell
10,236
-451
-4% -$112K 1.62% 1
2018
Q4
$2.39M Sell
10,687
-441
-4% -$103K 1.59% 2
2018
Q3
$2.72M Sell
11,128
-393
-3% -$90.4K 1.56% 4
2018
Q2
$2.39M Sell
11,521
-146
-1% -$31K 1.47% 11
2018
Q1
$2.41M Sell
11,667
-828
-7% -$174K 1.53% 5
2017
Q4
$2.37M Sell
12,495
-97
-0.8% -$18.6K 1.4% 10
2017
Q3
$2.38M Sell
12,592
-781
-6% -$141K 1.48% 5
2017
Q2
$2.33M Sell
13,373
-635
-5% -$107K 1.5% 4
2017
Q1
$2.15M Sell
14,008
-126
-0.9% -$19.3K 1.39% 12
2016
Q4
$1.99M Sell
14,134
-89
-0.6% -$13.1K 1.36% 12
2016
Q3
$2.26M Sell
14,223
-382
-3% -$58.9K 1.56% 2
2016
Q2
$2.16M Sell
14,605
-738
-5% -$109K 1.48% 5
2016
Q1
$2.17M Sell
15,343
-700
-4% -$93.8K 1.5% 1
2015
Q4
$2.28M Sell
16,043
-276
-2% -$36.8K 1.58% 2
2015
Q3
$2M Sell
16,319
-402
-2% -$52.4K 1.42% 9
2015
Q2
$2.17M Sell
16,721
-279
-2% -$36.4K 1.43% 4
2015
Q1
$2.28M Sell
17,000
-594
-3% -$76.6K 1.47% 5
2014
Q4
$2.2M Buy
17,594
+220
+1% +$26.8K 1.4% 11
2014
Q3
$2.11M Sell
17,374
-922
-5% -$112K 1.43% 8
2014
Q2
$2.16M Sell
18,296
-1,761
-9% -$207K 1.43% 12
2014
Q1
$2.41M Sell
20,057
-3,004
-13% -$357K 1.59% 2
2013
Q4
$2.57M Sell
23,061
-1,224
-5% -$122K 1.7% 2
2013
Q3
$2.24M Sell
24,285
-5,438
-18% -$492K 1.6% 1
2013
Q2
$2.52M Buy
+29,723
New +$2.47M 1.78% 1

Other funds holding TMO

Eads & Heald Wealth Management's TMO Position: Q1 2026 in Review

Eads & Heald Wealth Management reduced its Thermo Fisher Scientific (TMO) stake by 0.28% in Q1 2026, selling an estimated $6.51K and leaving 4,331 shares worth $2.13M. The position accounts for 1.06% of the portfolio, ranked #35.

Eads & Heald Wealth Management first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $4M in Q4 2021. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Eads & Heald Wealth Management held 4,331 shares of Thermo Fisher Scientific worth $2.13M as of Q1 2026.
  • Eads & Heald Wealth Management sold 12 Thermo Fisher Scientific shares in Q1 2026, an estimated $6.51K.
  • Thermo Fisher Scientific made up 1.06% of Eads & Heald Wealth Management's portfolio in Q1 2026, its #35 holding.
  • Eads & Heald Wealth Management first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
  • Eads & Heald Wealth Management's Thermo Fisher Scientific position peaked at $4M in Q4 2021.
  • 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Eads & Heald Wealth Management's 13F filing for Q1 2026, filed 29 Apr 2026.